Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product Pylarify and its competitive position during the specified class period [3][7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and is involved in securities and derivative litigation [5].

Group 1: Savara Inc. (SVRA) - A shareholder class action lawsuit has been filed against Savara Inc. alleging that the company made materially false and/or misleading statements regarding its biologics license application for MOLBREEVI between March 7, 2024, and May 23, 2025 [1] - Investors who purchased Savara shares during this period and suffered significant losses are encouraged to discuss their legal rights [1] Group 2: Fly-E Group, Inc. (FLYE) - A shareholder class action lawsuit has been filed against Fly-E Group, Inc. alleging that the company made materially false and/or misleading statements regarding its lithium battery, supply chain changes, regulatory environment, and demand fluctuations for E-Bikes and E-Scooters between July 15, 2025, and August 14, 2025 [2] - Investors who purchased Fly-E shares during this period and suffered significant losses are encouraged to discuss their legal rights [2] Group 3: Lantheus Holdings, Inc. (LNTH) - A shareholder class action lawsuit has been filed against Lantheus Holdings, Inc. alleging that the company created a false impression regarding its projected revenue outlook and anticipated growth while minimizing risks from competition, pricing dynamics, seasonality, and macroeconomic fluctuations between February 26, 2025, and August 5, 2025 [3] - Investors who purchased Lantheus shares during this period and suffered significant losses are encouraged to discuss their legal rights [3] Group 4: Holzer & Holzer, LLC - Holzer & Holzer, LLC is a top-rated securities litigation law firm that represents shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation [4] - The firm has recovered hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct since its founding in 2000 [4]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Lantheus Holdings, Inc. for misrepresentations regarding its key product, Pylarify, affecting investors who acquired securities between February 26, 2025, and August 5, 2025 [1][4][3] Group 1 - The lawsuit was initiated in the United States District Court for the Southern District of New York [3] - Investors are reminded of a deadline to file as lead plaintiff by November 10, 2025, with no fees or expenses required from shareholders [5] - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lantheus Holdings, Inc. securities between February 26, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline on November 10, 2025 [1] Group 1: Class Action Details - Investors who purchased Lantheus securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements to investors while concealing material adverse facts about Pylarify's competitive position [5] - It is claimed that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify, which led to a risk in its price point, revenue, and growth potential [5]

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the company's revenue outlook and growth potential, particularly related to Pylarify's market dynamics [2]. - It is alleged that Lantheus' optimistic reports on Pylarify's sales growth and pricing normalization did not reflect the actual market conditions, indicating a lack of accurate understanding of competitive dynamics [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to client service [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3][6]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lantheus Holdings, Inc. securities between February 26, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline on November 10, 2025 [1] Group 1: Class Action Details - Investors who purchased Lantheus securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3] - The lawsuit alleges that Lantheus provided misleading statements regarding its product Pylarify's competitive position and failed to disclose critical information about pricing dynamics [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4]

Core Insights - The FDA has set a Prescription Drug User Fee Act (PDUFA) date of March 29, 2026, for Lantheus Holdings' LNTH-2501, a diagnostic kit for neuroendocrine tumors [1][2] Company Overview - Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovative diagnostic solutions [5] - The company has been providing radiopharmaceutical solutions for nearly 70 years and operates globally with offices in multiple countries [5] Product Details - LNTH-2501 (Gallium-68 edotreotide) is designed for use with positron emission tomography (PET) imaging to localize somatostatin receptor-positive neuroendocrine tumors (SSTR+ NETs) in both adult and pediatric patients [1][4] - The product is submitted under the FDA's 505(b)(2) pathway, supported by extensive evidence from multiple published studies [2][4] - If approved, LNTH-2501 may complement Lantheus' therapeutic candidate PNT2003, enhancing the company's strategy for integrated diagnostic and therapeutic solutions [4] Market Context - Neuroendocrine tumors (NETs) are rare cancers, with over 170,000 individuals in the U.S. living with these conditions, and gastroenteropancreatic NETs (GEP-NETs) account for 55-70% of cases [3] - Due to their slow growth and non-specific symptoms, up to 50% of NETs are initially misdiagnosed, leading to delays in treatment [3]

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position during the specified class period [3][7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3] - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3] - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3] - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3] Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7] - There is no cost or obligation for investors to inquire about their claims [4] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5] - The firm has offices in New York, California, and South Carolina and handles cases in state and federal courts across the country [5]

Core Insights - Carillon Tower Advisers reported a continued upward trend in equity markets, driven by AI advancements, reduced inflation from tariffs, and potential interest rate cuts by the U.S. Federal Reserve [1] - The Russell 2000® Growth Index increased by 12.19% in Q3 2025, slightly underperforming the Russell 2000 Value Index, which rose by 12.60% [1] Company Analysis: Lantheus Holdings, Inc. (NASDAQ:LNTH) - Lantheus Holdings, Inc. is a manufacturer of diagnostic and therapeutic products, focusing on heart, cancer, and other diseases [2] - The stock experienced a one-month return of 11.78% but has seen a significant decline of 47.92% over the past 52 weeks, closing at $57.33 with a market cap of $3.898 billion on October 28, 2025 [2] - The company is facing challenges with its Pylarify product due to increased competition and difficulties in securing higher hospital reimbursement rates, leading to lowered guidance and no near-term pipeline products to alleviate pressure [3] Investment Sentiment - Lantheus Holdings, Inc. is not among the top 30 most popular stocks among hedge funds, with 34 hedge fund portfolios holding the stock at the end of Q2 2025, down from 43 in the previous quarter [4] - While Lantheus Holdings has potential, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry lower downside risk [4]